Tag HIV Prevention

Clinical Trials, News

Gilead Sciences announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial

Gilead Sciences announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.…

June 21, 2024

News, Social Impact, Statements

United Nations Secretary-General’s message on World AIDS Day 2023.

World AIDS Day arrives at a defining moment. AIDS-related deaths have fallen by almost 70 per cent since their peak in 2004, and new HIV infections are at the lowest point since the 1980s. But AIDS still takes a life…

December 1, 2023

Company News, New Treatments, News

EC authorises ViiV Healthcare’s Apretude for HIV prevention.

👉 Given as few as six times per year, cabotegravir has demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition in clinical trials.1,2,3,4 👉 With approximately 100,000 people newly diagnosed with…

September 19, 2023